Teladoc Inc (NYSE:TDOC) has been assigned an average rating of “Buy” from the sixteen analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $39.25.

Several research analysts have recently weighed in on the company. BidaskClub upgraded Teladoc from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. CIBC reiterated an “outperform” rating and set a $45.00 price target (up previously from $40.00) on shares of Teladoc in a research note on Tuesday, November 21st. KeyCorp reissued a “buy” rating and set a $37.00 price objective on shares of Teladoc in a report on Sunday, September 17th. Cantor Fitzgerald reissued a “hold” rating and set a $31.00 price objective on shares of Teladoc in a report on Tuesday, September 26th. Finally, Zacks Investment Research raised Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, September 21st.

Teladoc (NYSE TDOC) opened at $34.00 on Friday. The company has a current ratio of 5.08, a quick ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc has a 12 month low of $15.65 and a 12 month high of $37.90.

Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.25). The firm had revenue of $68.70 million for the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The firm’s revenue was up 112.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.33) EPS. analysts predict that Teladoc will post -1.56 earnings per share for the current fiscal year.

In other Teladoc news, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $32.99, for a total value of $3,299,000.00. Following the sale, the chief executive officer now owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Mark Hirschhorn sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $34.04, for a total value of $340,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 265,000 shares of company stock worth $8,697,400 in the last three months. 4.47% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in TDOC. Rosenblum Silverman Sutton S F Inc. CA increased its position in shares of Teladoc by 2.7% during the 2nd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 67,395 shares of the health services provider’s stock valued at $2,339,000 after purchasing an additional 1,800 shares during the last quarter. Bank of Montreal Can increased its position in shares of Teladoc by 214.2% during the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after purchasing an additional 2,397 shares during the last quarter. Raymond James Trust N.A. increased its position in shares of Teladoc by 36.2% during the 3rd quarter. Raymond James Trust N.A. now owns 9,943 shares of the health services provider’s stock valued at $330,000 after purchasing an additional 2,643 shares during the last quarter. American International Group Inc. increased its position in shares of Teladoc by 8.1% during the 3rd quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock valued at $1,196,000 after purchasing an additional 2,697 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Teladoc by 4.8% during the 2nd quarter. Swiss National Bank now owns 59,500 shares of the health services provider’s stock valued at $2,065,000 after purchasing an additional 2,700 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Teladoc Inc (TDOC) Given Average Rating of “Buy” by Analysts” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://theolympiareport.com/2017/12/15/teladoc-inc-tdoc-given-average-rating-of-buy-by-analysts.html.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with Analyst Ratings Network's FREE daily email newsletter.